Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon

Thomas A. Ullman, Robert Odze, Francis A. Farraye

Research output: Contribution to journalReview article

77 Citations (Scopus)

Abstract

To minimize the possibility of developing lethal colorectal cancer (CRC) in ulcerative colitis (UC) and Crohn's colitis, patients are usually enrolled in a program of dysplasia surveillance. The success of a surveillance program depends on the identification of patients with dysplasia and timely referral for colectomy. While a number of issues might stand in the way of a surveillance system achieving its maximal effect (less than ideal agreement in the interpretation of biopsy specimens, sampling error by endoscopists, delays in referral to surgery, and patient drop-out among others), circumstantial evidence supports the concept that colonoscopic dysplasia surveillance is an effective means of reducing CRC mortality and morbidity while minimizing the application of colectomy for cancer prevention. This review critically appraises key issues in the diagnosis and management of dysplasia in UC and Crohn's disease as well as adjunct efforts to prevent CRC in inflammatory bowel disease.

Original languageEnglish (US)
Pages (from-to)630-638
Number of pages9
JournalInflammatory Bowel Diseases
Volume15
Issue number4
DOIs
StatePublished - Jul 17 2009
Externally publishedYes

Fingerprint

Ulcerative Colitis
Crohn Disease
Colorectal Neoplasms
Colon
Colectomy
Referral and Consultation
Selection Bias
Colitis
Inflammatory Bowel Diseases
Morbidity
Biopsy
Mortality
Neoplasms

Keywords

  • Chemoprevention
  • Colorectal cancer
  • Crohn's disease
  • DALM
  • Dysplasia
  • Ulcerative colitis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Gastroenterology

Cite this

Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. / Ullman, Thomas A.; Odze, Robert; Farraye, Francis A.

In: Inflammatory Bowel Diseases, Vol. 15, No. 4, 17.07.2009, p. 630-638.

Research output: Contribution to journalReview article

@article{5677ee3caeb843018984f0329a759dcd,
title = "Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon",
abstract = "To minimize the possibility of developing lethal colorectal cancer (CRC) in ulcerative colitis (UC) and Crohn's colitis, patients are usually enrolled in a program of dysplasia surveillance. The success of a surveillance program depends on the identification of patients with dysplasia and timely referral for colectomy. While a number of issues might stand in the way of a surveillance system achieving its maximal effect (less than ideal agreement in the interpretation of biopsy specimens, sampling error by endoscopists, delays in referral to surgery, and patient drop-out among others), circumstantial evidence supports the concept that colonoscopic dysplasia surveillance is an effective means of reducing CRC mortality and morbidity while minimizing the application of colectomy for cancer prevention. This review critically appraises key issues in the diagnosis and management of dysplasia in UC and Crohn's disease as well as adjunct efforts to prevent CRC in inflammatory bowel disease.",
keywords = "Chemoprevention, Colorectal cancer, Crohn's disease, DALM, Dysplasia, Ulcerative colitis",
author = "Ullman, {Thomas A.} and Robert Odze and Farraye, {Francis A.}",
year = "2009",
month = "7",
day = "17",
doi = "10.1002/ibd.20766",
language = "English (US)",
volume = "15",
pages = "630--638",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon

AU - Ullman, Thomas A.

AU - Odze, Robert

AU - Farraye, Francis A.

PY - 2009/7/17

Y1 - 2009/7/17

N2 - To minimize the possibility of developing lethal colorectal cancer (CRC) in ulcerative colitis (UC) and Crohn's colitis, patients are usually enrolled in a program of dysplasia surveillance. The success of a surveillance program depends on the identification of patients with dysplasia and timely referral for colectomy. While a number of issues might stand in the way of a surveillance system achieving its maximal effect (less than ideal agreement in the interpretation of biopsy specimens, sampling error by endoscopists, delays in referral to surgery, and patient drop-out among others), circumstantial evidence supports the concept that colonoscopic dysplasia surveillance is an effective means of reducing CRC mortality and morbidity while minimizing the application of colectomy for cancer prevention. This review critically appraises key issues in the diagnosis and management of dysplasia in UC and Crohn's disease as well as adjunct efforts to prevent CRC in inflammatory bowel disease.

AB - To minimize the possibility of developing lethal colorectal cancer (CRC) in ulcerative colitis (UC) and Crohn's colitis, patients are usually enrolled in a program of dysplasia surveillance. The success of a surveillance program depends on the identification of patients with dysplasia and timely referral for colectomy. While a number of issues might stand in the way of a surveillance system achieving its maximal effect (less than ideal agreement in the interpretation of biopsy specimens, sampling error by endoscopists, delays in referral to surgery, and patient drop-out among others), circumstantial evidence supports the concept that colonoscopic dysplasia surveillance is an effective means of reducing CRC mortality and morbidity while minimizing the application of colectomy for cancer prevention. This review critically appraises key issues in the diagnosis and management of dysplasia in UC and Crohn's disease as well as adjunct efforts to prevent CRC in inflammatory bowel disease.

KW - Chemoprevention

KW - Colorectal cancer

KW - Crohn's disease

KW - DALM

KW - Dysplasia

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=67650121080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650121080&partnerID=8YFLogxK

U2 - 10.1002/ibd.20766

DO - 10.1002/ibd.20766

M3 - Review article

VL - 15

SP - 630

EP - 638

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 4

ER -